PARP Inhibitors are a New Class of Targeted-Therapy Which Can Improve Killing of Advanced Prostate Cancer Cells
PARP inhibitors were initially developed to treat cancers in people who inherited BRCA1 or BRCA2 gene mutations.
These drugs were originally approved by the FDA to treat breast cancer. Presently, four PARP inhibitors have received FDA approval for treatment of breast, ovarian, pancreatic, and prostate cancer.
Even though prostate cancer clinical trials show extremely promising results, there is still a need for more Black male participation in these clinical trials for a better understanding of the impact of this new class of drugs in the Black prostate cancer patient population.
The promising results of PARP inhibitors in metastatic castration resistant prostate cancer (mCRPC) patients, has prompted the initiation of PARP inhibitor clinical trials targeting earlier-stage prostate cancer at the hormone sensitive stage.
TALAPRO-3 is one such clinical trial studying a possible treatment for men with metastatic hormone sensitive prostate cancer with a DDR gene alteration. The clinical trial is looking at how effective and safe the study drug, talazoparib, is when taken in combination with enzalutamide, an existing, approved treatment for mCRPC.